Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
N Engl J Med. 2022.
PMID: 35139274
Clinical Trial.